93. The compound of claim 90, wherein the compound is represented by the structural formula: or a pharmaceutically acceptable salt thereof. 94. The pharmaceutical composition of claim 91, wherein the compound is represented by the structural formula: or a pharmaceutically acceptable salt thereof.Des...
5.The platform system of claim 1, wherein said mounting plate comprises:an under surface configured to be disposed to face the bottom surface of the cooking space; anda plurality of adjustable mounts, each being configured to adjust its respective height so as to collectively adjust a space bet...
This claim needs further confirmation, however, since the mutation used in this study, YY340/341FF, has only a moderate effect on C-Raf kinase activity [23] and the residual activity may suffice for its function. A more definitive examination will require a “knock in” of a mutation that...
6. The compound of claim 1 wherein the compound of formula II is selected from the group consisting of 3-{5-[2-({(3R)-1-[(4-chlorophenyl)sulfonyl]piperidin-3-yl}amino)pyrimidin-4-yl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl carbamate, 3-{5-[2-({(3R)-1-[(4-chlorophenyl)sul...
67. The method of claim 66, wherein the compound is of formula: 68. The method of claim 66, wherein the suitable base is lithium hydroxide. 69. The method of claim 66, wherein the suitable acid is acetic acid.Description: PRIORITY The present application claims priority under 35 U.S...
11. The method of claim 8, wherein said cellular transformation phenotype is induced by a ras oncogene product. Description: BACKGROUND OF THE INVENTION Field of the Invention The present invention relates, in general, to methods of inducing a therapeutic effect. In particular, the present invent...
31. The method of claim 29, wherein the cancer is a carcinoma. 32. The method of claim 31, wherein the carcinoma is squamous cell carcinoma. 33. The method of claim 31, wherein the carcinoma is adenoma or adenocarcinoma. 34. The method of claim 29, wherein the cancer is breast, ov...